Combination therapies against cancer: new opportunities for transnational research
Basic Information
Despite advances in targeted therapies, immunotherapies, or radiotherapy, different obstacles, and challenges remain to be solved. Current limitations of in vitro personalized systems allowing a fast and reliable testing, new platforms to achieve combination therapy screening, new methods to achieve synergism in combination therapy and new combinations of radiotherapy with drugs or immunotherapy, remain, slowing down further applications of combination therapy in the clinic. Thus, there is a need for the identification of new and fast strategies to assay for individualized combination therapies that may help in the clinic to overcome tumour resistance and improve clinical outcomes avoiding undesired side effects. This topic should evolve from the laboratory to favour the clinical implementation of the strategies from the bench to the bedside.
| Network | TRANSCAN-3 | ||||||||
| Website | https://transcan.eu/news-and-resources/updates/preliminary-announcement-upcoming-call-jtc-2024.kl | ||||||||
| Aim of the joint call | The main purpose of this call will be design of patient preclinical models for combination therapies. Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. | ||||||||
| Type of joint call | Two Stages - Call with pre-proposals and full proposals submissions | ||||||||
| Events |
|
||||||||
| Is call co-funded? | No | ||||||||
| Call follow up funding | n/a | ||||||||
| Call reasons | n/a | ||||||||
| Research fields |
|
||||||||
| Type of research | n/a | ||||||||
| Target groups | n/a | ||||||||
| Participating networks | n/a |